OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
3
Results
Show all
Save search
Copy query
Show results for
Unknown
(3)
Publication Date
Release Date
2017
(2)
2024
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
Not available
S-EPMC5559878
|
biostudies-literature
Cite
Physician-reported patient involvement and treatment decisions in first-line ovarian cancer in the USA and Europe.
Not available
S-EPMC11671897
|
biostudies-literature
Cite
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Not available
S-EPMC5706109
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
